References
- Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol. 2022;60(2):143–158.
- Ott M, Mannchen JK, Jamshidi F, et al. Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques. Ther Adv Psychopharmacol. 2019;9:2045125318818814.
- Magalhães P, Alves G, LL A, et al. Clinical drug-drug interactions: focus on venlafaxine. Drug Metab Pers Ther. 2015;30(1):3–17.
- Nisijima K, Shioda K, Yoshino T, et al. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int. 2003;43(2):155–164.
- Van Buren PN, Inrig JK. Mechanisms and treatment of intradialytic hypertension. Blood Purif. 2016;41(1–3):188–193.
- Boulestreau R, van den Born BH, Lip GYH, et al. Malignant hypertension: current perspectives and challenges. J Am Heart Assoc. 2022;11(7):e023397.
- Nguyen H, Pan A, Smollin C, et al. An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California poison control system. J Clin Pharm Ther. 2019;44(2):327–334.
- Werneke U, Jamshidi F, Taylor DM, et al. Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases. BMC Neurol. 2016;16:97.